Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use

Choosing Wisely for genitourinary cancers

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Best practice in precision medicine for prostate cancer

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC